Top Endocrinology Research Papers

Overall: A strong phase 3 trial shows exceptionally large weight loss with meaningful improvements in knee pain and sleep-apnea severity, but incomplete safety reporting and real-world access burdens temper its immediate impact.

Overall: A large randomized trial supports meaningful kidney and possible survival benefits from semaglutide in a highly relevant primary-care population, though the subgroup design and absent safety information limit certainty about net benefit.

Overall: This rigorous, highly applicable meta-analysis shows that routine calcium or vitamin D supplementation offers little to no fracture or fall prevention benefit for most community-dwelling adults.

Overall: This large randomized-trial synthesis is clinically influential and directly applicable to US obesity care, but limited head-to-head comparisons, sparse hard-outcome evidence, increased adverse-event discontinuation, and absent absolute effects temper confidence in the net benefit.

Overall: Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. — Strong pooled randomized evidence shows a precise, moderate reduction in major kidney outcomes with similar overall safety, although absolute benefit and treatment burden are incompletely reported and regimen heterogeneity limits a uniform practice directive.

Overall: A large, methodologically strong systematic review supports remote diabetes care during pregnancy as a practical and generally safe alternative, with possible maternal and neonatal benefits but unresolved absolute effect size, equity, and long-term outcome questions.

Overall: This large, precise randomized trial analysis shows a modest absolute but clinically important survival benefit in high-risk patients, with practical impact limited by unreported safety and treatment-burden data.

Overall: Evolocumab produced credible reductions in major cardiovascular events and mortality among patients with high-risk diabetes, but missing absolute MACE and safety data plus cost and injection burdens temper the net benefit and immediate practice impact.

Overall: This strong prespecified analysis found clinically meaningful reductions in first cardiovascular events and mortality, but the moderate absolute benefit, injectable treatment burden, and unreported harms temper its immediate impact on primary care.

Overall: Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy: Large randomized-trial data link baseline lipid status to clinically important coronary outcomes and offer a practical risk-selection approach, but subgroup analysis, imprecision, regimen specificity, and absent absolute effects limit immediate practice change.